Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers

被引：33
作者：
Rexer, Brent N.
Ghosh, Ritwik
Arteaga, Carlos L. [1 ]
机构：
[1] Vanderbilt Univ, Sch Med, Div Oncol, Dept Med, Nashville, TN 37232 USA
来源：
CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 14期
关键词：
CANCER; MTOR; ACTIVATION;
D O I：
10.1158/1078-0432.CCR-09-0872
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers. (Clin Cancer Res 2009;15(14) July 2009).
引用
收藏
页码：4518 / 4520
页数：3
相关论文
共 50 条
[31]   Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations [J].
LoPiccolo, Jaclyn ;
Blumenthal, Gideon M. ;
Bernstein, Wendy B. ;
Dennis, Phillip A. .
DRUG RESISTANCE UPDATES, 2008, 11 (1-2) :32-50
[32]   Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells [J].
Leelawat, Kawin ;
Narong, Siriluck ;
Udomchaiprasertkul, Wandee ;
Leelawat, Surang ;
Tungpradubkul, Sumalee .
CANCER CELL INTERNATIONAL, 2009, 9
[33]   Inhibition of the PI3K Pathway: Hope We Can Believe in? [J].
van der Heijden, Michiel S. ;
Bernards, Rene .
CLINICAL CANCER RESEARCH, 2010, 16 (12) :3094-3099
[34]   Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer [J].
Cirone, Pasquale ;
Andresen, Catharine J. ;
Eswaraka, Jeetendra R. ;
Lappin, Patrick B. ;
Bagi, Cedo M. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) :525-538
[35]   Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer [J].
Butler, Dominika E. ;
Marlein, Christopher ;
Walker, Hannah F. ;
Frame, Fiona M. ;
Mann, Vincent M. ;
Simms, Matthew S. ;
Davies, Barry R. ;
Collins, Anne T. ;
Maitland, Norman J. .
ONCOTARGET, 2017, 8 (34) :56698-56713
[36]   Dual Targeting of MEK and PI3K Pathways Attenuates Established and Progressive Pulmonary Fibrosis [J].
Madala, Satish K. ;
Edukulla, Ramakrishna ;
Phatak, Mukta ;
Schmidt, Stephanie ;
Davidson, Cynthia ;
Acciani, Thomas H. ;
Korfhagen, Thomas R. ;
Medvedovic, Mario ;
LeCras, Timothy D. ;
Wagner, Kimberly ;
Hardie, William D. .
PLOS ONE, 2014, 9 (01)
[37]   Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy [J].
Li, Qingfang ;
Li, Zhihui ;
Luo, Ting ;
Shi, Huashan .
MOLECULAR BIOMEDICINE, 2022, 3 (01)
[38]   Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma [J].
Westin, Jason R. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) :335-342
[39]   PI3K inhibition as a novel therapeutic strategy for neoadjuvant chemoradiotherapy resistant oesophageal adenocarcinoma [J].
Edge, Sarah D. ;
Renard, Isaline ;
Pyne, Emily ;
Li, Chun ;
Moody, Hannah ;
Roy, Rajarshi ;
Beavis, Andrew W. ;
Archibald, Stephen J. ;
Cawthorne, Christopher J. ;
Maher, Stephen G. ;
Pires, Isabel M. .
BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1119)
[40]   Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition [J].
Tang, K. D. ;
Ling, Ming-Tat .
CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) :3048-3056
12345